Biopharma is deeply unpopular. Saving some lives could help
The coronavirus outbreak has escalated into a global crisis, overburdening health care workers abroad and stoking fears in the U.S. For the drug industry, it could be just an opportunity to shine.
As STAT’s Nicholas Florko reports, the outbreak finds biopharma at a reputational nadir in Washington, where lowering the cost of medicine is among vanishingly few bipartisan causes, uniting even Sen. Bernie Sanders and President Trump.
But as the administration struggles to contain the virus in the U.S., the many drug companies at work on treatments and vaccines have the chance to do well by doing good, provided they can seize the moment and come up with something that makes a difference.
“It’s like a reset button for them,” said Pallavi Kumar, a communications professor at American University who previously worked for Wythe Pharmaceuticals. “In times of crisis people want heroes, even if those heroes were villains in the past.”
Read more.
As STAT’s Nicholas Florko reports, the outbreak finds biopharma at a reputational nadir in Washington, where lowering the cost of medicine is among vanishingly few bipartisan causes, uniting even Sen. Bernie Sanders and President Trump.
But as the administration struggles to contain the virus in the U.S., the many drug companies at work on treatments and vaccines have the chance to do well by doing good, provided they can seize the moment and come up with something that makes a difference.
“It’s like a reset button for them,” said Pallavi Kumar, a communications professor at American University who previously worked for Wythe Pharmaceuticals. “In times of crisis people want heroes, even if those heroes were villains in the past.”
Read more.
.png)
No hay comentarios:
Publicar un comentario